InnoCare wins China IND clearance to trial PSMA/STEAP1 bispecific ADC ICP-B381

• China’s NMPA drug regulator cleared InnoCare to start clinical trials of ICP-B381, a bispecific ADC targeting PSMA and STEAP1.
• Candidate is slated for solid tumors, with an initial focus on prostate cancer.
• InnoCare said no PSMA/STEAP1 bispecific ADC has been approved for sale globally.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609082226PRIMZONEFULLFEED9823495) on September 09, 2026, and is solely responsible for the information contained therein.